Market Overview

DaVita HealthCare Shares Slip Amid Raymond James Downgrade

Share:
Related DVA
Earnings Scheduled For May 4, 2016
Bernstein Lowers DaVita's Price Target, Believes Dialysis Biz Is Well Positioned For Long-Term Growth
DaVita HealthCare Partners (DVA) Kent J. Thiry on Q1 2016 Results - Earnings Call Transcript (Seeking Alpha)

In Monday's morning summary, Raymond James analyst John Ransom downgraded shares of DaVita HealthCare Partners (NYSE: DVA) from Outperform to Market Perform and removed his $75 price target.

Ransom noted the downgrade is in reaction to the announcement that HealthCare Partners' president and CEO, Dr. Craig Samitt, will be stepping down effective August 1. Being that Samitt was only appointed back in March, Ransom said, at best, this means the company made an "ill-timed error in judgement."

In addition to this announcement, Ransom noted that HealthCare Partners has suffered from a series of disappointments, and to become more constructive he needs to see more clarity, which he doesn't expect until the company's July 31 earnings announcement.

Following news of Samitt's departure and the note from Ransom, Shares of DaVita have dipped more than three percent.

Latest Ratings for DVA

DateFirmActionFromTo
Mar 2016BernsteinMaintainsMarket Perform
Sep 2015JP MorganInitiates Coverage onNeutral
Apr 2015BairdUpgradesNeutralOutperform

View More Analyst Ratings for DVA
View the Latest Analyst Ratings

Posted-In: John Ransom Raymond JamesAnalyst Color Downgrades Price Target Analyst Ratings Movers

 

Related Articles (DVA)

View Comments and Join the Discussion!